Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

JAMA

Volumn 302, Issue 7, 2009, Pages 750-757

  Slade, Barbara A ^a   Leidel, Laura ^a   Vellozzi, Claudia ^a   Woo, Emily Jane ^b   Hua, Wei ^b   Sutherland, Andrea ^b   Izurieta, Hector S ^b   Ball, Robert ^b   Miller, Nancy ^b   Braun, M Miles ^b   Markowitz, Lauri E ^a   Iskander, John ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; WART VIRUS VACCINE;

ANAPHYLAXIS; ARTICLE; AUTOIMMUNE DISEASE; BAYES THEOREM; CELLULITIS; CONVULSION; DATA MINING; DISEASE SEVERITY; DIZZINESS; DRUG DISTRIBUTION; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNIZATION; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LICENSING; LUNG EMBOLISM; MOTOR NEURON DISEASE; MYELITIS; NAUSEA; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION; SYNCOPE; URTICARIA; VENOUS THROMBOEMBOLISM; VERRUCA VULGARIS; WART VIRUS;

EID: 68949133346     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1201     Document Type: Article

References (34)

1. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, 18] vaccine, recombinant): product information and supporting documents. Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm094042.htm. Accessed July 27, 2009.
2. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
3. Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
4. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007;369(9576):1861-1868.
5. Garland S, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med. 2007;356(19):1928-1943.
6. Block SL, Nolan T, Sattler C, et al; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135-2145.
7. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J. 2004;23(4):287-294.
8. Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine: United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48(27):577-581.
9. Medical Dictionary for Regulatory Activities. http://www.meddramsso.com/ MSSOWeb/index.htm. Accessed July 10, 2007.
10. Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994;12(6):542-550.
11. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177-190.
12. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157-166.
13. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25(6):381-392.
14. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483-486.
15. Evans S. Statistical methods in signal detection. In: Pharmacovigilance. Mann RD, Andrews EB, eds. Chichester, UK: John Wiley & Sons; 2002:273-279.
16. Centers for Disease Control and Prevention (CDC). Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006;55(41):1120-1124.
17. Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ. Guillain-Barré syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol. 1981;9(suppl):31-38.
18. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110(2):105-123.
19. Brighton Collaboration Guillain-Barré Syndrome Working Group. http://www.brightoncollaboration.org/internet/en/index/working-groups/ case-definition-working/ongoing/guillain-barre-syndrome.html. Accessed May 12, 2008.
20. Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. http://hcupnet.ahrq.gov/. Accessed July 23, 2009.
21. Rüggeberg JU, Gold MS, Bayas JM, et al; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675-5684.
22. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment [March 2005]. Food and Drug Administration. http: //www.fda.gov/downloads/RegulatoryInformation /Guidances/UCM126834.pdf. Accessed January 30, 2008.
23. Chen RT, Glasser JW, Rhodes PH, et al; The Vaccine Safety Datalink Team. Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99(6):765-773.
24. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164(18):1965-1976.
25. Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med. 1997;151(3):255-259.
26. Woo EJ, Ball R, Braun MM. Fatal syncope-related fall after immunization. Arch Pediatr Adolesc Med. 2005;159(11):1083.
27. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC; Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep. 2002;51(RR-2):1-35.
28. American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
29. Centers for Disease Control and Prevention (CDC). Syncope after vaccination: United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457-460.
30. Lin JT, Ziegler DK, Lai CW, Bayer W. Convulsive syncope in blood donors. Ann Neurol. 1982;11(5):525-528.
31. Roddy SM, Ashwal S, Schneider S. Venipuncture fits: a form of reflex anoxic seizure. Pediatrics. 1983;72(5):715-718.
32. Weber JC. Epidemiology of adverse reactions to non-steroidal antiinflammatory drugs. Adv Inflamm Res. 1984;6:1-7.
33. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS): United States, 1991-2001. MMWR Surveill Summ. 2003;52(1):1-24.
34. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16(3):336-341.